Clinical trial
STEM-PD Trial: A Multicentre, Single Arm, First in Human, Dose-escalation Trial, Investigating the Safety and Tolerability of Intraputamenal Transplantation of Human Embryonic Stem Cell Derived Dopaminergic Cells for Parkinson's Disease (STEM-PD Product)
NCT05635409 is registered in ClinicalTrials.gov with Region Skane as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- STEM-PD Trial: A Multicentre, Single Arm, First in Human, Dose-escalation Trial, Investigating the Safety and Tolerability of Intraputamenal Transplantation of Human Embryonic Stem Cell Derived Dopaminergic Cells for Parkinson's Disease (STEM-PD Product)
- Lead sponsor
- Region Skane
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- November 30, 2022
- Completion date
- November 30, 2027
- Enrollment
- 8 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.